OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% is added to ophthalmic
irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for
maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.
OMIDRIA® and the OMIDRIA logo® are registered trademarks of Omeros Corporation.
© Omeros Corporation 2018, all rights reserved. 2018-063
• Prevents Intraoperative Floppy Iris Syndrome (IFIS)
1
• Reduces complication rates (epinephrine comparator)
2
• Decreases use of pupil-expanding devices (epinephrine comparator)
2-7
• Reduces surgical times (epinephrine comparator)
2,4,6,7
• Prevents miosis during femtosecond laser-assisted surgery (epinephrine comparator)
5,8
• Improves uncorrected visual acuity on day after surgery (epinephrine comparator)
2
• Delivers NSAID to the anterior chamber and related structures better than routine preoperative
topical drug administration, resulting in effectively complete postoperative inhibition of COX-1
and COX-2
9,10
The data are compelling and consistent—OMIDRIA makes cataract surgery
better for you and your patients
Published and presented clinical studies report that in post-launch (i.e., not included in current
labeling), prospective and retrospective, double-masked and open-label, cohort and case-
controlled, single- and multi-center analyses, the use of OMIDRIA, compared to the surgeons'
standard of care, statistically significantly:
Contact your OMIDRIA representative today or visit omidria.com to learn more
Separately reimbursed under Medicare Part B
IMPORTANT SAFETY INFORMATION
OMIDRIA must be added to irrigating solution prior to intraocular use.
OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.
Systemic exposure of phenylephrine may cause elevations in blood pressure.
Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid,
phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past
medical history of asthma.
The most commonly reported adverse reactions at ≥ 2% are eye irritation,
posterior capsule opacification, increased intraocular pressure, and anterior
chamber inflammation.
Please see the Full Prescribing Information for OMIDRIA at
www.omidria.com/prescribinginformation.
You are encouraged to report Suspected Adverse Reactions
to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
